Anixa Biosciences(ANIX)

Focus: Anixa Biosciences is a public-stage diagnostics and cell therapy company focused on CAR-T treatments and cancer immunotherapy, headquartered in San Jose with minimal current commercial footprint.

Cell Therapy

Profile data last refreshed 19h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Anixa Biosciences

AI assessmentNot Hiring

No open roles listed right now. Follow Anixa Biosciences to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$210K

Pipeline & Clinical Trials

Follicle Stimulating Hormone Receptor T Cells

Ovarian Cancer

Phase 1

Clinical Trials (1)

NCT05316129Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer

Phase 1

Help build intelligence for Anixa Biosciences

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage pipeline with novel modalities (CAR-T, therapeutic vaccines) offers opportunity to shape drug development from Phase 1 — rare in established companies
Public company status provides liquidity and potential equity upside without late-stage execution risk
Focused portfolio (2 active programs) allows deep specialization in cell therapy and immuno-oncology

Watch Out For

Severe financial distress: $1M cash (FY2025), $12.6M net loss, and <$210K revenue signals existential funding risk within 12–24 months
Zero active job openings and minimal headcount indicate no hiring; company is in survival/fundraising mode, not growth mode
Only Phase 1 programs with no Phase 2+ data; 5–10 year timelines to any potential revenue; no near-term validation catalysts

Generated by Claude from Anixa Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Alpha-lactalbumin vaccine

Triple-Negative Breast Cancer

Phase 1

Clinical Trials (1)

NCT04674306Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer

Phase 1

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 2 clinical trials

Top TAs: Oncology

SEC Filings: 2 available

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

2 pipeline

Marketed

Pipeline

Financials (FY2025)

R&D Spend

$6M34%

Net Income

-$13M

Cash

$1M

Source: SEC 10-K Filing